Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CFTR | P13569 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.33 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.32 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.31 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3854602 | 0.85 | CFTR (0.33) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3108529 | 0.75 | MAPT (0.37) | CYP19A1CDK2SMN1; SMN2MAPK1MEN1 | |
| SCHEMBL3859248 | 0.71 | CDK2 (0.58) | CCNA2CDK2CCNA1CDK5DYRK1A | |
| SCHEMBL3304341 | 0.69 | MAPK13 (0.30) | — | |
| SCHEMBL14250064 | 0.68 | ADORA3 (0.38) | CYP19A1CDK2CDK5CDK5R1SMN1; SMN2 | |
| SCHEMBL27574655 | 0.68 | KCNA5 (0.39) | CCNA2CDK2CCNA1CDK5DYRK1A | |
| SCHEMBL3852234 | 0.68 | KDM4C (0.49) | SMN1; SMN2MAPK1MEN1ALDH1A1KMT2A | |
| SCHEMBL2494591 | 0.67 | CFTR (0.58) | CYP19A1CFTRSLC6A2SLC6A4SLC6A3 | |
| Niacinamide SCHEMBL9164041 | 0.67 | F7 (0.50) | CCNA2CDK2SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL2194465 | 0.67 | BCDIN3D (0.46) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846696-B2 | Purine derivatives | CYCLACEL LIMITED (GB) | 2014-09-30 | — | — | US | disclosed |
| US-20090325983-A1 | NEW PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2009-12-31 | — | — | US | disclosed |
| US-7582642-B2 | 4-{9-Isopropyl-6-[(pyridin-3-ylmethyl)-amino]-9H-purin-2-ylamino}-2-methyl-hexan-3-ol;antiproliferative agents; viricides; alopecia; strokes; central nervous system diorders; neurodegenerative diseases; antidiabetic agents; mitosis; cyclin dependent kinase inhibitors; protein kinase inhibitors | CYCLACEL LIMITED (GB) | 2009-09-01 | — | — | US | disclosed |
| EP-1529047-B1 | NEW PURINE DERIVATIVES | CYCLACEL LTD (GB) | 2007-02-21 | — | — | EP | disclosed |
| EP-1529047-A2 | NEW PURINE DERIVATIVES | Cyclacel Limited (GB) | 2005-05-11 | — | — | EP | disclosed |
| WO-2004016612-A2 | NEW PURINE DERIVATIVES | CYCLACEL LIMITED (GB) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325983-A1 | NEW PURINE DERIVATIVES | C5, CYC1, CCNH | CYP19A1 1050/4885CFTR 1058/4885SLC6A2 2094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.